Ivantis Raises $25 Million Series C to Fund Future US Commercialization of the Hydrus™ Microstent for Minimally Invasive Glaucoma Surgery (MIGS)

09 January 2017

Ivantis Inc., developer of the novel Hydrus™ Microstent device designed to lower eye pressure for glaucoma patients, announced today that it closed a $25 million Series C financing. The round was led by new investor RA Capital Management, and included new investor Mérieux Développement, as well as existing investors. The funds will extend Ivantis’ runway […]

Continue Reading